Kornimate/medical-research-clean huggingface dataset:
diabetes lifestyle assessment and educational tools

Conditions: Type 2 Diabetes Mellitus

Summary: aim: to evaluate a culturally-adapted method of lifestyle assessment, counseling, and education among arab people with diabetes who have varying literacy skills using an interactive computerized tool and graphically-enhanced patient logs for dietary and physical activity. the investigators hypothesize that this tool will: a) increase patients' knowledge and understanding of the role of lifestyle (diet and physical activity) in diabetes management; b) improve patients' engagement in monitoring dietary intake and physical activity; c) improve dietary and physical activity behaviors and self-blood glucose monitoring (sbgm) practices; d) improve glycemic control; and, e) improve the efficiency of lifestyle assessment, education and counseling while increasing patients' engagement in the process.

aim: to evaluate a culturally-adapted method of lifestyle assessment, counseling, and education among arab people with diabetes who have varying literacy skills using an interactive computerized tool and graphically-enhanced patient logs for dietary and physical activity. the investigators will evaluate the effectiveness of this method for: a) increasing patients' knowledge and understanding of the role of lifestyle (diet and physical activity) in diabetes management; b) improving patients' engagement in monitoring dietary intake and physical activity; c) improving dietary and physical activity behaviors and self-blood glucose monitoring (sbgm) practices; d) improving glycaemic control; and, e) improving the efficiency of lifestyle assessment, education and counseling while increasing patients' engagement in the process.

Eligibility criteria:
inclusion criteria: * 40-64 years old * bmi 27-45 kg/m2 * diagnosis of type 2 diabetes mellitus in medical record * hba1c 8.0%-11.5% exclusion criteria: * short-acting insulin treatment * inadequate control of co-morbid conditions * factors that may limit adherence to interventions (e.g., any medical or physical condition that limits the ability to participate in physical activity or standard diets recommended for people with diabetes, pregnancy, uncontrolled psychiatric condition, significant cognitive impairment, blindness).

Keywords: type 2 diabetes mellitus lifestyle counselling lifestyle assessment randomized controlled trial diabetes education
role of dutasteride in treatment of chronic prostatitis

Conditions: Dutasteride; Category IIIB Chronic Prostatitis

Summary: this placebo controlled study aims to evaluate the efficacy of dutasteride in the management of chronic prostatitis type 3.

nonbacterial prostatitis refers to a condition that affects patients who present with symptoms of prostatitis without a positive culture for urine or expressed prostate secretions (eps). with time our understanding of prostatitis was evolved to include a different clinical phenotype with a variety of voiding presentation and symptomatology rather than just inflammation and infection. the two main clinical presentations of prostatitis include pelvic pain and luts. the national institutes of health and the national institute of diabetes and digestive and kidney diseases (nih-niddk) proposed the first classification of prostatitis into 4 categories in 1995 that was later published in 1998. bacterial prostatitis represented category i and iii while nonbacterial prostatitis including chronic prostatitis/chronic pelvic pain syndrome (cp/cpps) was categorized as category iii that was further subdivided into class iiia (inflammatory cpps) and b (non-inflammatory cpps). category iv encompasses asymptomatic inflammatory prostatitis. shoskes et al, mentioned that inflammation and the upregulation of cytokine expression and release in the prostate secondary to an inflammatory process led to the presenting symptoms in such a condition. the recently introduced upoint phenotype categorization of cp/cpps (urinary, psychosocial, organ-specific, infection, neurological/systemic, tenderness of the skeletal muscles). this categorization shows up to 60% of men have at least prostate organ associated symptoms. the prostate lies under the hormonal control of dihydrotestosterone (dht); thus 5 alpha-reductase inhibitors (5aris) might be beneficial in the treatment of prostatitis. dutasteride is a 5α-reductase inhibitor, and hence is a type of anti-androgen. it works by decreasing the production of (dht) in certain parts of the body like the prostate gland. it inhibits all three forms of 5α-reductase and can decrease dht levels in the blood by up to 98%. 5aris have been previously evaluated on a narrow scale in the management of prostatitis with promising results of safety and efficacy.

Eligibility criteria:
inclusion criteria: * patients aged between 40 and 70 years old, diagnosed with chronic prostatitis based on the presence of pelvic pain for ≥3 months of the preceding 6 months exclusion criteria: patients with bacterial prostatitis * documented site of infection along the urinary tract, * urinary bladder tumors * prostate cancer * previous history of pelvic radiation or chemotherapy were excluded from our study.
s0437 long-term follow-up of patients who were diagnosed with prostate cancer on pcpt

Conditions: Prostate Cancer

Summary: rationale: learning about the long-term effects of chemoprevention drugs, such as finasteride, in patients with prostate cancer may help doctors plan better treatment and follow-up care. purpose: this clinical trial is following patients who were diagnosed with prostate cancer while undergoing treatment with either finasteride or a placebo on the prostate cancer prevention trial (pcpt).

objectives: * compare the time to metastases in patients who were diagnosed with high grade or low grade prostate cancer on or before december 31, 2003 and were treated with finasteride or placebo while enrolled on the prostate cancer prevention trial (swog-9217). * compare the difference in time to secondary therapy after definitive therapy with radiotherapy or radical prostatectomy in these patients. * compare the difference in time to prostate-specific antigen recurrence after definitive therapy with radiotherapy or radical prostatectomy in these patients. * compare the difference in all-cause and prostate cancer mortality in these patients. outline: this is a multicenter study. patients are stratified according to survival status (alive vs deceased). patients provide information about their general health, prostate cancer treatment history, prostate cancer status (i.e., disease progression and metastases data), and prostate-specific antigen (psa) test results at baseline and then every 6 months for up to 8 years. next of kin of deceased patients are asked to release the patients' medical records in order to obtain information about the patients' prostate cancer treatment history, prostate cancer progression and metastases, psa test results, and cause of death. projected accrual: a minimum of 75% of the 2,401 patients (n=1800) diagnosed with prostate cancer on pcpt are needed to have minimal power to evaluate the objectives.

Eligibility criteria:
inclusion criteria: * randomized on pcpt * diagnosed with prostate cancer on or before december 31, 2003 disease characteristics: * diagnosed by either study site or central pathology review patient characteristics: * see inclusion criteria prior concurrent therapy: * not applicable

Keywords: recurrent prostate cancer stage i prostate cancer stage ii prostate cancer stage iii prostate cancer stage iv prostate cancer
airway clearance for pediatric and adult cystic fibrosis patients using a portable intra-pulmonary percussion device

Conditions: Cystic Fibrosis

Summary: this is a pilot study where the investigators aim to compare initial use of the standard airway clearance device (sacd), most commonly used being high frequency vest airway clearance system (vest) with subsequent use of a portable intra-pulmonary percussion device (piapd) in patients with cystic fibrosis (cf) ages 6 -21 years. the primary hypothesis is that there is no effect of piapd on forced expiratory volume in 1 second (fev1) 2 hours after use, there is no effect on perception of effort and efficacy for the piapd. if both are equally effective, the latter device provides an alternative that is both cheaper and portable.


Eligibility criteria:
inclusion criteria: * ages 6-21 years * cystic fibrosis stable by physician assessment * assents to forego additional experimental treatments during the study * currently using and familiar with airway clearance therapy for treatment of cystic fibrosis * participant (or parent or legal guardian if the participant is a minor) is willing to provide -----informed consent exclusion criteria: * fev1 \< 40% predictive * pneumothorax * hemoptysis * coronavirus disease (covid) 19 diagnosis within last 14 days * any condition that, in the opinion of the investigator, would interfere with the study conduct or the safety of the participant * additional exclusion criteria: outpatient arm (in addition to general exclusion criteria above) decrease in fev1 \> 10% from baseline over last 12 months antibiotic initiation for acute cf exacerbation hospitalization for cf exacerbation * additional exclusion criteria: inpatient arm (in addition to general exclusion criteria above) failure to increase fev1 \> 10 % from initial pulmonary function testing (pfts) on admission by day 9 of hospitalization.

Keywords: airway clearance
neulasta® in subjects with advanced non-small-cell lung cancer (nsclc) during chemotherapy

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of this study is to estimate the relationship between patient reported outcomes (pros) and neutropenia (or its complications) in nsclc subjects receiving chemotherapy with or without neulasta® (pegfilgrastim).


Eligibility criteria:
inclusion criteria: - non-small cell lung cancer, not previously treated with chemotherapy or radiotherapy - ecog performance status 0 or 1 - anc greater than or equal to 2.0 x 10\^9/l exclusion criteria: - cancer other than nsclc within 5 years of enrollment, with the exception of surgically cured basal cell carcinoma or in situ carcinoma of the cervix - treatment less than or equal to 30 days prior with any experimental agent - subjects with symptomatic brain metastases - subject is currently enrolled or has not yet completed at least 30 days since ending other investigational device or drug trial(s) or is receiving other investigational agent(s)

Keywords: non small cell lung cancer nsclc fever neutropenia neulasta® quality of life chemotherapy amgen
olanzapine versus placebo in the treatment of mania in adolescents with bipolar i disorder

Conditions: Bipolar Disorder

Summary: the purpose of this study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of mania in bipolar disorder in adolescents. both the potential benefits and side effects of olanzapine will be evaluated throughout this trial.


Eligibility criteria:
inclusion criteria: * male or female patients, 13 to 17 years of age who must not yet have reached their 18th birthday prior to visit 1, when informed consent is obtained. * patients must have a diagnosis of bipolar i disorder and currently display an acute mania or mixed episode. * both the patient and the patient's parent/authorized legal representative must understand the nature of the study and must sign a document granting consent. * female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. exclusion criteria: * female patients who are either pregnant or nursing. * current diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder. * patient with acute or unstable medical conditions, such that intensive care unit hospitalization for the disease is anticipated within 6 months. * patients who have previously not responded to an adequate dose and/or duration of olanzapine treatment. * patients who have been judged clinically to be serious suicidal risks.
an internet-based weight loss and exercise intervention for breast cancer survivors

Conditions: Breast Cancer

Summary: the purpose of this study is to test the effectiveness of a behavioral weight loss and exercise intervention delivered via the internet at different cancer centers in new england. the investigators hypothesize that participants will lose 7% of their body weight. the research is being done because many women who are treated for breast cancer are overweight and treatment for breast cancer is often accompanied by weight gain. individuals who are overweight may be more likely to have their breast cancer come back. also women who exercise at least three hours a week seem to have less chance of their cancer coming back. the investigators hope to identify an effective weight loss and exercise intervention for breast cancer survivors that can be easily accessed by many people. this study is designed to determine the feasibility of conducting a distantly delivered-weight loss and exercise intervention for patients who have been treated for breast cancer at three cancer centers, and to evaluate the efficacy of an internet-based behavioral weight loss and exercise intervention delivered to overweight/obese breast cancer survivors in three new england locations. participants will be recruited from three new england cancer centers - the vermont cancer center, norris cotton cancer center at dartmouth university and the university of massachusetts cancer center. participants from each center will undergo baseline assessments that include diet assessment, body measurements (height, weight, etc), a physical activity assessment and be asked to complete a series of questionnaires. patients that meet the minimum requirements will be enrolled on the study. they will participate in weekly on-line "chats" about behavioral and diet modifications led by a qualified facilitator. participants will also engage in increasing amounts of aerobic activity (typically walking) throughout the course of the intervention. the intervention lasts 6 months. at the end of those 6 months, participants will have the same assessments that were collected at baseline. following the collection of those assessments, participants will have completed the study.


Eligibility criteria:
inclusion criteria: * breast cancer diagnosis * completion of surgery, chemotherapy +/- radiation for stage i, ii, or iii breast cancer 2-12 months prior to study initiation * bmi between 27 and 50 * patient self-report of ability to walk for 10 minutes without interruption or pain * access to computer and the internet exclusion criteria: * metastatic disease * prior receipt of chemotherapy for other malignancy * pregnancy at the time of study entry * limited food choices due to celiac sprue or inflammatory bowel disease * illiteracy * non-english speaking

Keywords: breast cancer survivor weight loss exercise
effects of dietary fiber on insulin sensitivity

Conditions: Focus of the Study is Insulin Sensitivity

Summary: this study will examine the effects of a dietary fiber on insulin sensitivity in overweight and obese women. the fiber will be added to snack foods and women will consume the foods for four weeks. in one four-week period, 15 g of fiber will be added, and 30 g will added in another period. in a third period, no fiber will be added to the snack foods. insulin senstivity will be measured at the end of each treatment period.


Eligibility criteria:
inclusion criteria: * impaired fasting glucose * overweight and obese exclusion criteria: * diabetes, presence of chronic diseases

Keywords: insulin sensitivity resistant starch
zürich pulmonary hypertension outcome assessment cohort

Conditions: Pulmonary Hypertension Outcome Assessment

Summary: ph is a serious disease with a dismal prognosis and impaired quality of life when left untreated. reliable patient centered and prognostically relevant outcome measures are highly warranted in the field of ph. with this prospective cohort study the investigators intend to gain important information on the course of the disease and knowledge on the value of different new and already established outcome parameters.

ph is a serious disease with a dismal prognosis and impaired quality of life when left untreated. advances in medical therapy have improved survival according to recent registries, but are associated with high healthcare costs. most treatment trials and clinical follow-up assessments rely on the 6 minute walk distance as main outcome parameter although submaximal exercise performance reflects only one disease aspect. reliable patient centered and prognostically relevant outcome measures are highly warranted in the field of ph. with this prospective cohort study the investigator intend to gain important information on the course of the disease and knowledge on the value of different new and already established outcome parameters. new outcomes to be assessed will be home based activity monitoring, novel physiological measures, namely cerebral and muscle tissue oxygenation at rest and during exercise testing, stair ascent on mechanograph, sit to stand test and several serum markers and micro-rna. all these assessments will be compared with hard endpoints events (death, lung-transplantation, hospitalization for ph), and with traditional outcome measures such as nyha functional class, 6 minute walk distance, generic quality of life, cardiopulmonary exercise tests, sleep studies, health preference (utility) and cognitive function.

Eligibility criteria:
inclusion criteria: * patients with precapillary pulmonary hypertension * adult male and female patients of all ages referred to our center for evaluation/treatment of ph * written informed consent by the subject after information about the research project exclusion criteria: * patients with severe concomitant left heart disease (left ventricular ejection fraction \<40%). * patients with restrictive lung disease (fvc\<60% predicted); obstructive lung disease (forced expiratory volume (fev) \<60% predicted, with fev 1/fvc\<70%). * patients with any other disease limiting their ability to move (skeletal disease, neurological disease, etc.)

Keywords: pulmonary hypertension chronic thromboembolic pulmonary hypertension pulmonary arterial hypertension outcome
horizons hiv intervention

Conditions: HIV Infections; Sexually Transmitted Diseases

Summary: the horizons program will test the efficacy of a multi-session hiv prevention program for african american female teens attending reproductive health clinics in atlanta, ga.

african-american adolescent females are a population at high risk for hiv infection. recent findings suggest that culturally and gender appropriate hiv interventions can significantly reduce hiv-associated sexual risk behaviors among this vulnerable population. the horizons hiv intervention was developed for african-american female adolescents attending reproductive health clinics in atlanta, ga. the specific objectives were: 1. to evaluate the efficacy of the horizons hiv intervention plus standard of care counseling versus the standard of care counseling alone in reducing self-reported hiv sexual risk behaviors and incident stds over a 12 month follow-up period. 2. to evaluate the cost-effectiveness of the horizons hiv intervention plus standard of care counseling to the standard of care counseling alone with respect to reducing risky sexual behavior and averting incident stds. 715 participants, ages 15-21, were recruited and enrolled at a large urban county health department, a teen clinic in a public hospital and a reproductive health clinic in the atlanta area. after a computer interview assessing adolescents' sexual risk and preventive behaviors, and std testing (chlamydia and gonorrhea), participants were randomized to one of 2 conditions: the horizons intervention or the standard-of-care counseling group. two trained female health educators lead the 2-session horizons intervention which addressed gender and ethnic pride issues, std/hiv knowledge, assertive partner communication and refusal skills, and role-play practice. social cognitive theory (sct) and the theory of gender and power were complementary theoretical frameworks guiding the design and implementation of the hiv intervention. to supplement this group intervention, four phone contacts delivered by the original health educator were conducted during the follow-up period. the supplemental contacts reinforced workshop materials with an individually tailored plan for each participant. the control group received tracking calls only. follow-up assessments identical to the baseline were conducted at 6 and 12-months post-randomization.

Eligibility criteria:
inclusion criteria: * female * african american * ages 15-21 * receiving care at participating clinic * vaginal sex in the past 60 days * ability to give written informed consent exclusion criteria: * married * pregnant * in a detention center

Keywords: hiv sexually transmitted diseases adolescents prevention hiv seronegativity
assessment the efficacy of acetyl-l-carnitine in patient with alzheimer's disease

Conditions: Alzheimer Disease

Summary: clinical trial to assess the efficacy of acetyl-l-carnitine

a multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of acetyl-l-carnitine in patient with alzheimer's disease

Eligibility criteria:
inclusion criteria: * more than 50 years * probable alzheimer disease according to dsm-iv and nincds-adrda standard * 12≤k-mmse(screening)≤26 * be able to perform examinations * patient taking donepezil(5mg or 10mg/day) more than 3 months * be able to visit to hospital with caregiver exclusion criteria: * possible or probable or definite vascular dementia according to ninds-airen standard * cns disease(cerebrovascular diseases, epilepsy etc) to cause dementia * illiteracy * patient taking galantamine, memantine, rivastigmine within three months * patient taking brain enhancer, thyroid hormone within 4 weeks * patient taking central nervous system stimulant, antipsychotic agent, anticholinergic agent within 2 weeks * at screenig blood test: ast, alt≥ 3 x upper limit of normal range or hb≤8g/dl or platelet\<100,000/mm3 or serum creatinine ≥ 3 x upper limit of normal range * abnormal result of vit.b12, syphilis serology, tsh * severe depression, schizophrenia, alcoholism, drug addiction * parkinson's disease (need to drug therapy) * angina, myocardial infarction, ischemia within six months * head injury with sense of loss within six months * patient taking other ip within three months * hypersensitivity to ip * sever hearing problems or visual impairment